Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ivabradine
Drug ID BADD_D01218
Description Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.
Indications and Usage Ivabradine's indication by the FDA is to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.
Marketing Status Prescription
ATC Code C01EB17
DrugBank ID DB09083
KEGG ID D07165
MeSH ID D000077550
PubChem ID 132999
TTD Drug ID D0S9QA
NDC Product Code 70518-3309; 55513-813; 65977-0116; 55513-800; 55513-810
Synonyms Ivabradine | 7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one | S 16257 | S-16257 | S16257 | S 16257-2 | S 16257 2 | S 162572 | S-16257-2 | S162572 | S-16260-2 | S162602 | S 16260-2 | S 16260 2 | S 162602 | Corlanor
Chemical Information
Molecular Formula C27H36N2O5
CAS Registry Number 155974-00-8
SMILES CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hallucination19.10.02.0020.000303%
Headache17.14.01.0010.001516%
Heart rate abnormal13.14.04.0060.000910%Not Available
Heart rate decreased13.14.04.0010.001112%Not Available
Heart rate increased13.14.04.0020.002527%Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.000707%
Hypertensive crisis24.08.01.0010.000202%Not Available
Hyperuricaemia14.09.01.003--
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.0020.001516%
Influenza22.07.02.001; 11.05.03.0010.000202%Not Available
Insomnia19.02.01.002; 17.15.03.002--
Joint swelling15.01.02.0040.000202%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.000404%
Loss of consciousness17.02.04.004--Not Available
Lung disorder22.02.07.0010.000202%Not Available
Malaise08.01.01.0030.001415%
Migraine24.03.05.003; 17.14.02.0010.000404%Not Available
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Oedema14.05.06.010; 08.01.07.0060.000202%Not Available
Oropharyngeal swelling07.05.04.002; 23.04.01.013; 22.04.05.005; 10.01.05.0140.000202%Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.0200.000202%Not Available
Pain in extremity15.03.04.010--
Palpitations02.01.02.0030.001011%
Panic attack19.06.04.0010.000404%Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages